Nasdaq provided the Company 60 days to submit a plan to regain compliance with the Rule with respect to delinquent reports (the “Plan”).
Key Points:
- Nasdaq provided the Company 60 days to submit a plan to regain compliance with the Rule with respect to delinquent reports (the “Plan”).
- The Company intends to submit its plan of compliance to Nasdaq by June 18, 2024.
- If Nasdaq accepts the Plan, the Company may be granted an extension of 180 calendar days from the due date of the Form 10-K, or until October 14, 2024, to regain compliance with the Rule.
- In the event the Plan is not accepted by Nasdaq, the Company may appeal that decision to a Hearings Panel.
Nasdaq provided the Company 60 days to submit a plan to regain compliance with the Rule (the “Plan”).
Key Points:
- Nasdaq provided the Company 60 days to submit a plan to regain compliance with the Rule (the “Plan”).
- The Company intends to submit its plan of compliance to Nasdaq by June 18, 2024.
- If Nasdaq accepts the Plan, the Company may be granted an extension of 180 calendar days from the due date of the Form 10-K, or until October 14, 2024, to regain compliance with the Rule.
- In the event the Plan is not accepted by Nasdaq, the Company may appeal that decision to a Hearings Panel.
Retrieved on:
Wednesday, January 3, 2024
New York, Jan. 03, 2024 (GLOBE NEWSWIRE) -- BIMI Holdings Inc. (NASDAQ: BIMI) (“BIMI” or the “Company”), previously known as (BIMI International Medical Inc.) a healthcare products and services provider, today announced the results of the Company’s 2022 Annual General Meeting of Stockholders (the “Annual Meeting”) held on Dec 29, 2023 at 11:00 a.m. at the offices of the Company, 725 5th Ave, New York, NY 10022.
Key Points:
- New York, Jan. 03, 2024 (GLOBE NEWSWIRE) -- BIMI Holdings Inc. (NASDAQ: BIMI) (“BIMI” or the “Company”), previously known as (BIMI International Medical Inc.) a healthcare products and services provider, today announced the results of the Company’s 2022 Annual General Meeting of Stockholders (the “Annual Meeting”) held on Dec 29, 2023 at 11:00 a.m. at the offices of the Company, 725 5th Ave, New York, NY 10022.
- At the Annual General Meeting the shareholders voted and approved;
1.
- The election of seven directors to serve on the board of directors of the Company, until the next annual meeting of Stockholders and until their respective successors have been duly elected and qualified;
2.
- On a non-binding advisory basis, annual non-binding advisory votes on resolutions approving named executive officer compensation (“Say When on Pay Vote”); and
6.
Retrieved on:
Tuesday, December 19, 2023
NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (the “Company”), a leading medical solutions provider, today announced its financial results for the three months and nine months ended September 30, 2023.
Key Points:
- NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (the “Company”), a leading medical solutions provider, today announced its financial results for the three months and nine months ended September 30, 2023.
- Revenues for the three months ended September 30, 2023 and 2022 were $2,523,193 and $4,932,479, respectively.
- Revenues for the nine months ended September 30, 2023 and 2022 were $11,278,496 and $10,476,224, respectively.
- Net loss for the three months ended September 30, 2023 and 2022 was $3,134,072 and $3,099,662, respectively, while net loss for the nine months ended September 30, 2023 and 2022 was$1,146,581 and $12, 214,649, respectively.
Retrieved on:
Tuesday, November 28, 2023
NEW YORK, NY, Nov. 28, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ: BIMI, "BIMI"), a healthcare products and services provider, today announced its entry into material definitive agreements with certain of its warrant holders, pursuant to which BIMI agreed to buy back an aggregate of 7,066,913 warrants to purchase shares of common stock of the Company from these warrant holders.
Key Points:
- NEW YORK, NY, Nov. 28, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ: BIMI, "BIMI"), a healthcare products and services provider, today announced its entry into material definitive agreements with certain of its warrant holders, pursuant to which BIMI agreed to buy back an aggregate of 7,066,913 warrants to purchase shares of common stock of the Company from these warrant holders.
- BIMI agreed to pay $0.30 for each share of common stock underlying the warrant, or an aggregate purchase price of $2,120,073.80 to the warrant holders within three (3) business days (for certain sellers), or two (2) months (for certain other sellers), of the signing of the agreements.
- The warrants will be deemed cancelled upon the receipt by the sellers of the purchase price.
Retrieved on:
Monday, November 27, 2023
NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (the “Company”), a leading medical solutions provider, today announced its financial results for the three months ended June 30, 2023.
Key Points:
- NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (the “Company”), a leading medical solutions provider, today announced its financial results for the three months ended June 30, 2023.
- The Company reported a significant increase in gross margin underlining the ongoing success of its business strategy and operational effectiveness.
- Revenues for the six months ended June 30, 2023 and 2022 were $8,755,303 and $5,543,745, respectively.
- "We are delighted with the initial success achieved by Phenix Bio Inc.”, said Mr. Tiewei Song, the CEO of BIMI International Medical Inc.
Retrieved on:
Monday, November 27, 2023
Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission.
Key Points:
- Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission.
- The Nasdaq letter has no immediate effect on the listing of the Company’s shares.
- The Nasdaq letter also stated that previously Nasdaq had granted the Company an exception until December 8, 2023, to file its delinquent Form 10-Q for the period ended June 30, 2023 (the “Initial Delinquent Filing”).
- The Company intends to resolve the deficiency with respect to the Third Quarter Form 10-Q and regain compliance with the Nasdaq Listing Rules.
Retrieved on:
Wednesday, November 8, 2023
NEW YORK, NY, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Phenix Bio Inc., a wholly owned subsidiary of BIMI International Medical Inc. (NASDAQ: BIMI), a leading global healthcare provider, announces the official launch of its "CUCA 3.0 Product Line through China Duty Free Group's (CDFG) online mini program sales platform.
Key Points:
- NEW YORK, NY, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Phenix Bio Inc., a wholly owned subsidiary of BIMI International Medical Inc. (NASDAQ: BIMI), a leading global healthcare provider, announces the official launch of its "CUCA 3.0 Product Line through China Duty Free Group's (CDFG) online mini program sales platform.
- This significant milestone means China Duty Free’s 26 million members can now purchase Phenix’s products directly from CDFG, solidifying the previous purchase agreement between Phenix and CDFG, which became effective on August 1, 2023.
NEW YORK, NY, Oct. 30, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ: BIMI, “BIMI”), a healthcare products and services provider today announced that its subsidiary, Phenix Bio Inc., appointed Hao Mu Pte.
Key Points:
- NEW YORK, NY, Oct. 30, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ: BIMI, “BIMI”), a healthcare products and services provider today announced that its subsidiary, Phenix Bio Inc., appointed Hao Mu Pte.
- Ltd., a Singapore company (“Hao Mu”), as its exclusive distributor responsible for the distribution of Phenix’s 17 herbal supplements in Hong Kong, Taiwan and Macau.
- “We are excited to extend our agreement with Hao Mu,” stated Tiewei Song, CEO of BIMI.
- Hao Mu was previously appointed as Phenix’s exclusive distributor for the ten-member ASEAN countries.
NEW YORK, NY, Oct. 30, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ: BIMI, “BIMI”), a healthcare products and services provider today announced that its subsidiary, Phenix Bio Inc., appointed Hao Mu Pte.
Key Points:
- NEW YORK, NY, Oct. 30, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ: BIMI, “BIMI”), a healthcare products and services provider today announced that its subsidiary, Phenix Bio Inc., appointed Hao Mu Pte.
- Ltd., a Singapore company (“Hao Mu”), as a distributor responsible for the distribution of Phenix’s 17 herbal supplements in Mainland China.
- “Expanding our partnership with Hao Mu to Mainland China shows our faith in Hao Mu and its ability to make our products available to wider markets” stated Tiewei Song, CEO of BIMI.
- This extension of its partnership with Hao Mu evidences BIMI’s commitment to deliver world-class healthcare solutions and services to a broader global audience.
